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Abstract: Chitosan, a natural polymer, is a promising system for the therapeutic delivery of both 
plasmid DNA and synthetic small interfering RNA. Reports attempting to identify the optimal 
parameters of chitosan for synthetic small interfering RNA delivery were inconclusive with 
high molecular weight at high amine-to-phosphate (N:P) ratios apparently required for efficient 
transfection. Here we show, for the first time, that low molecular weight chitosan (LMW-CS) 
formulations at low N:P ratios are suitable for the in vitro delivery of small interfering RNA. 
LMW-CS nanoparticles at low N:P ratios were positively charged (ζ-potential ∼20 mV) with 
an average size below 100 nm as demonstrated by dynamic light scattering and environmental 
scanning electron microscopy, respectively. Nanoparticles were spherical, a shape promoting 
decreased cytotoxicity and enhanced cellular uptake. Nanoparticle stability was effective for at 
least 20 hours at N:P ratios above two in a slightly acidic pH of 6.5. At a higher basic pH of 8, 
these nanoparticles were unravelled due to chitosan neutralization, exposing their polynucle-
otide cargo. Cellular uptake ranged from 50% to 95% in six different cell lines as measured by 
cytometry. Increasing chitosan molecular weight improved nanoparticle stability as well as the 
ability of nanoparticles to protect the oligonucleotide cargo from nucleases at supraphysiological 
concentrations. The highest knockdown efficiency was obtained with the specific formulation 
92-10-5 that combines sufficient nuclease protection with effective intracellular release. This 
system attained .70% knockdown of the messenger RNA, similar to commercially available 
lipoplexes, without apparent cytotoxicity. Contrary to previous reports, our data demonstrate 
that LMW-CS at low N:P ratios are efficient and nontoxic polynucleotide delivery systems 
capable of transfecting a plethora of cell lines.
Keywords: siRNA, nonviral delivery system, chitosan, gene silencing, RecQL1, ApoB
Introduction
RNA interference (RNAi), an evolutionary endogenous gene regulation mechanism 
based on double-stranded RNA (short hairpin RNA, microRNA, Piwi-interacting 
RNA, and small interfering RNA [siRNA]), has provided a potential new class of 
therapeutics.1 Since its discovery in Caenorhabditis elegans,2 RNAi has been proven 
effective in mammalian cells1,3–11 and has reached clinical trials.1,12–14 However, direct 
delivery of RNAi-inducing entities such as synthetic siRNA or short hairpin RNA 
continues to be problematic owing to their rapid extracellular/intracellular degradation 
by nucleases (ie, RNAse and DNAse), limited blood stability, poor cellular uptake, 
and nonspecific targeting.15–17 As a consequence, the translation of RNAi into a clinical 
therapeutic reality is still pending resolution of these issues.
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Chemical modification of synthetic siRNAs has provided 
resistance to nuclease degradation and improved blood 
stability.18–22 For example, selective addition of a phospho-
rothioate linkage or substitution with 2′-O-methyl on the C2 
position of specific riboses increases nuclease resistance of 
siRNAs without compromising activity.14,19,20 Nevertheless, 
some chemical modifications can increase cytotoxicity, 
off-target effects and reduce messenger RNA (mRNA) 
hybridization.23–27 Despite progress achieved through chemi-
cal modification to increase siRNA half-life, transfection effi-
ciency, cellular targeting, and uptake remain as obstacles to 
effective delivery. Therefore, packaging systems which can 
both protect and transport chemically unmodified/ modified 
siRNA to target cells are required.
Liposomes/Lipoplexes have been extensively used as 
nonviral vehicles for plasmid and RNAi entities and pose 
toxicity concerns. For example, the repeated administration 
of lipid-based delivery vehicles caused phospholipidosis.28 
Intravenous injection of stable nucleic acid-lipid particles 
has successfully targeted the liver to silence the apolipo-
protein B (ApoB) gene in mice and nonhuman primates.10 
However, a significant 20-fold transient elevation in serum 
transaminases (aspartate transaminase, alanine transaminase) 
indicative of hepatocellular necrosis was identified at the 
effective dose. Liposomal formulations of nucleic acids are 
known inducers of inflammatory cytokines including tumor 
necrosis factor-alpha, interferon-gamma, and interleukin-6 
which may be related to liver damage.29 Polyethylene glycol 
(PEG) modification of liposomes (PEGylation), for the 
purpose of reducing their toxicity, was also demonstrated to 
elicit acute hypersensitivity after repeated dosing.30–32 Simi-
larly, the highly studied cationic family of polymers such as 
polyethylenimine demonstrated high gene transfer efficiency 
but was also associated with significant toxicity issues1,33 
limiting their broad use in clinical trials. Polyethylenimine 
cytotoxicity was characterized as a two-phase process where 
the polycation-cell interaction induces loss of cell membrane 
integrity and the induction of programmed cell death. Insights 
into polyethylenimine toxicity highlight the importance of 
polycation/organelle interactions – ie, mitochondria and 
lysosomes – on the induction of toxicity.34,35 In general, cat-
ionic polymers display less toxicity associated with cytokine 
induction – immune activation – compared to their cationic 
lipid counterparts.36
Chitosan, a family of cationic polymers of β-1-4 N-acetyl-
glucosamine and D-glucosamine residues, has been exten-
sively studied for the delivery of plasmid DNA (pDNA) 
and siRNA both in vitro and in vivo.3,8,17,37–43 Chitosan 
properties include mucoadhesivity,44 biocompatibility, 
biodegradability,45 nontoxicity, and low cost of production. 
Primary amine residues confer a polycationic nature to 
chitosan at pH values below its pKa (∼6.5) thus enabling it 
to condense polyanionic compounds such as nucleic acids. 
Electrostatic interaction between chitosan and nucleic acids 
leads to the spontaneous formation of nanoparticles of 
different sizes and shapes.46 The ability of chitosan-based 
nanoparticles to transfect cells efficiently depends on several 
parameters such as: (1) the degree of deacetylation (DDA), 
which represents the fraction of ionizable monomers; (2) the 
average molecular weight (M
n
), proportional to chain length, 
and (3) the amine-to-phosphate (N:P) charge ratio repre-
sented by the amine-(chitosan)-to-phosphate (DNA or RNA) 
ratio used to form nanoparticles.
We have previously demonstrated that maximization of 
in vitro transfection efficiency for the delivery of pDNA 
depends on a fine balance between these tunable parameters 
of chitosan38–40 and found maximum transgene expression for 
DDA:M
n
 values that run along a diagonal from high DDA/
low M
n
 to low DDA/high M
n
.38 We have also demonstrated 
that specific chitosan formulations [DDA, M
n
, and N:P ratio] 
efficiently express transgene in vivo.37,41
We also demonstrated that specific formulations are able 
to trigger an anti-transgene immune response;37 therefore, 
nanoparticles can be designed based on the fine-tuning of 
chitosan parameters for application-specific purposes such 
as genetic vaccination or gene therapy.
The structural differences between pDNA and siRNA 
are believed to affect the complexation/stability of nano-
particles and optimal parameters required for effective 
delivery. Chitosan has also been used for siRNA delivery 
both in vitro and in vivo.1,8,10,17,43 However, and despite 
attempts to identify optimal physicochemical parameters for 
siRNA delivery,43 inconclusive results have been observed 
in the literature due to experimental discrepancies.8,17 For 
example, it was reported that intermediate DDA (80%) 
and high Mw (64–170 kDa) chitosan were more efficient 
than low molecular weight chitosan (LMW-CS) (10 kDa) 
in delivering siRNA.17,43 However, high molecular weight 
chitosans are found to be cytotoxic,47–49 thus potentially 
limiting their use in future clinical trials. Additionally, most 
of the reports evaluating the physicochemical parameters of 
chitosan/siRNA nanoparticles were performed at high N:P 
ratios (N:P .25).8,17,43 Such formulations bring significant 
practical problems including limited dosing due to aggrega-
tion and the nonspecific effects of large quantities of soluble 
chitosan.50 Here, we investigate, for the first time, the ability 
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of specific LMW-CS formulations (92-10-5, 80-80-10, 
80-40-5, and 80-10-10) [DDA, M
n
, and N:P ratio] at low 
N:P ratios to in vitro deliver siRNA targeting: (1) the RecQL1 
DNA helicase mRNA in the colon adenocarcinoma RecQL1 
overexpressing cell line (LS174T) and (2) ApoB mRNA in 
the hepatocarcinoma-derived cell line (HepG2). The choice 
of these two targets resides in their relevance to cancer and 
atherosclerosis, respectively.6,7,9,51,52 We also explored the 
ability of these formulations to transfect multiple cell lines 
such as A549, AsPC1, HEK293, and Raw264.7 without 
apparent toxicity. In this study, we hypothesized that, contrary 
to previous literature,8,17,42,43 low Mw chitosans (LMW-CS) 
complexed at low N:P ratios represent suitable formulations 
for siRNA delivery and gene knockdown; similar to our 
observations with pDNA.37–41 Additionally, we hypothesized 
that low N:P ratios assure sufficient protection and efficient 
delivery of the siRNA cargo. Moreover, we explore the 
physicochemical properties of these specific formulations 
with the prospect of optimizing nanoparticle transfection 
and silencing efficiencies. Our results demonstrate, for the 
first time, that LMW-CSs at low N:P ratios are effective and 
nontoxic delivery systems for polynucleotide and siRNA 
delivery for in vitro gene silencing.
Materials and methods
Synthesis of sirNAs and dsODNs 
siRNAs targeting the RecQL1 DNA helicase and ApoB 
mRNAs were synthesized using a novel RNA synthesis chem-
istry, the 5′-silyl-2′-orthoester protecting groups (2′-ACE)54 
combined with a standard phosphoramitide solid-phase tech-
nology by Dharmacon (Thermo Scientific, Dharmacon RNAi 
Technologies, Lafayette, CO). RecQL1 mRNA-specific 
siRNA (siRNA-RecQL1) contains the sense sequence of 
5′-GUUCAGACCACUUCAGCUUdTdT-3′ and antisense 
5′-AAGCUGAAGUGGUCUGAACdTdT-3′ whereas ApoB 
mRNA-specific siRNA (siRNA-ApoB) contains the sense 
sequence of 5′-GUCAUCACACUGAAUACCAAU-3′ and 
antisense 5′-AUUGGUAUUCAGUGUGAUGACAC-3′. 
Mock siRNA was also used as a negative control. Mock siRNA 
is a nontargeting siRNA (Dharmacon, D-001710-01-05) 
designed to have minimal targeting of known genes in human, 
mouse, and rat cells.
Double-stranded oligodeoxynucleotides (dsODNs, 
21 bp) encoding the same sequences and mimicking 
siRNA physicochemical properties were used for 
nanoparticle characterization. The double-stranded 
oligodeoxynucleotide (dsODN) sequences were synthesized 
using the phosphoramidite chemistry (Integrated DNA 
Technologies Inc, Coralville, IO) and used for size and 
zeta potential determination, nanoparticle stability, and 
nuclease protection assays. For confocal microscopy and flow 
cytometry analysis, 6-carboxyfluorescein (6FAM) 5′-labeled 
dsODNs were used (Integrated DNA Technologies Inc). 
The rationale for using dsODN for chitosan nanoparticle 
physicochemical characterization is their siRNA-mimicking 
properties. These mimicking properties are due to similarities 
at the structural level (double-stranded structure, length, 
and nucleotide overhangs) between siRNA and dsODNs. 
Additionally, charge densities are similar between siRNA 
and dsODNs due to identical phosphate residue numbers on 
their backbone. The main differences between siRNA and 
dsODNs lie in the substitution of uracil to thymine (U → T) 
in the dsODN sequences, and in the deoxyribosilation of the 
dsODN sugar backbone.
Preparation and characterization  
of depolymerized chitosan
Clinical-grade chitosan at different DDAs was obtained from 
BioSynthec Inc, (Laval, QC, Canada) and depolymerized 
using nitrous acid to achieve specific number-average 
molecular weight targets (M
n
) of 80, 40, and 10 kDa. Chitosan 
number- and weight-average molecular weights (M
n
 and M
w
) 
were determined by gel permeation chromatography using 
a Shimadzu LC-20AD isocratic pump, autosampler 
SIL-20AC HT, oven CTO-20AC coupled with a Dawn 
HELEOS II multiangle laser light scattering detector 
(Wyatt Technology Co, Santa Barbara, CA), a Viscostar II 
(Wyatt Technology Co), an Optilab rEX interferometric 
refractometer (Wyatt Technology Co), and two Shodex 
OHpak (SB-806M HQ and SB-805 HQ; Showa Denko 
America, Inc, New York, NY) columns eluted with a pH 4.5 
acetic acid (0.15 M)/sodium acetate (0.1 M)/sodium azide 
(4 mM) buffer.54,55 The injection volume was 100 µL, the 
flow rate 0.8 mL min−1 and the temperature 25°C. The dn/dc 
value was previously calculated for chitosan with a DDA 
of 92% (for a laser’s wavelength of 658 nm) and is equal 
to 0.208 and 0.201 for chitosan with 80% DDA. The degree 
of deacetylation was determined by 1H NMR according to 
our previous reports.38,56
Preparation of chitosan nanoparticles
Chitosans with specific M
n
 and DDA (Table 1) were dissolved 
overnight on a rotary mixer at 0.5% (w/v) in hydrochloric 
acid using a glucosamine:HCl ratio of 1:1 at a final con-
centration of 5 mg/mL. Sterile filtered solutions were then 
diluted with deionized water to obtain the desired ratio 
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(N:P) of amine (chitosan deacetylated groups) to phosphate 
(dsODNs/siRNA nucleic acids). Nanoparticles (92-10-5, 
80-10-10, 80-40-5, and 80-80-5) were then prepared by 
rapid mixing (pipetting) of 100 µL of diluted chitosan solu-
tion to 100 µL of dsODNs or siRNA at a concentration of 
0.05 µg/µL or 100 nM.
Nanoparticle size and ζ-potential analysis
The size of chitosan/dsODN-RecQL1 and chitosan/dsODN-
ApoB nanoparticles – intensity average diameter – was 
determined by dynamic light scattering at an angle of 173° 
at room temperature using the Malvern Zetasizer Nano ZS 
(Malvern, Worcestershire, UK). Following nanoparticle for-
mation, samples were diluted in 10 mM NaCl at a ratio of 1:10 
and measured in triplicate. The ζ-potential was measured in 
triplicate using laser Doppler velocimetry at 25°C on the 
same instrument with the viscosity and dielectric constant 
of pure water used for calculations.
Environmental scanning electron 
microscopy (ESEM)
Chitosan/dsODN-RecQL1 and chitosan/dsODN-ApoB nano-
particles were sprayed on silicon wafer substrate then sputter-
coated with gold (Agar Manual Sputter Coater;  Marivac 
Inc, Montreal, QC, Canada) and imaged using a Quanta 200 
FEG Environmental Scanning Electron Microscope (FEI 
Inc, Hillsboro, OR). Observations were performed at 20 kV 
using the high-vacuum mode. The average particle diameter 
(± standard deviation) was determined using the XT Docu 
image analysis software (FEI Inc).
Nanoparticle stability assessment  
by polyacrylamide gel electrophoresis
The stability of chitosan/dsODN nanoparticles at differ-
ent pHs (6.5 and 8) and for different incubation times 
(0.5, 4, and 24 hours) was assessed using polyacrylamide 
gel electrophoresis. Upon formation, nanoparticles were 
mixed at a ratio of 1:1 with 2-(N-morpholino)ethanesulfonic 
acid buffer (MES 1X) (20 mM MES, 8 mM sodium acetate, 
pH 6.5) or  Tris-acetate (TAE)-EDTA buffer (TAE 1X) (2 M 
Tris-acetate, 50 mM EDTA, pH 8). The samples were then 
migrated on a 13% polyacrylamide gel (BioRad Laborato-
ries, Mississauga, ON, Canada) for 2 hours at 100 mV in 
either MES or TAE buffer. Gels were stained with 0.5 µg/mL 
ethidium bromide solution (BioRad Laboratories) to visual-
ize dsODNs. Gel documentation and image analysis were 
performed using a Bio-Vision 3000 (Vilbert Lourmat, 
Marne-la-Vallée, France) and the Vision-Capt software, 
respectively.
Nuclease protection assay
The level of protection against nuclease attack offered by 
chitosan formulations (92-10-5, 80-80-10, 80-40-5, and 
80-80-5) was assessed electrophoretically on a 5% agarose 
gel. Chitosan/dsODN-RecQL1 and chitosan/dsODN-ApoB 
nanoparticles at different DDA, M
w
, and N:P ratios were 
incubated with 0.5, 1, 2, 5, or 10 units of DNAse I (Sigma-
Aldrich, Oakville, ON, Canada) per µg of dsODNs in 20 µL 
of MES-MgCl
2
 buffer (20 mM MES, 1 mM MgCl
2
, pH 6.5) 
for 30 minutes at 37°C. The reaction was stopped by adding 
2 µL of EDTA (50 mM) (Sigma-Aldrich). To ensure proper 
migration of the nondigested dsODNs, samples were treated 
with Streptomyces griseus type III chitosanase (Sigma-Aldrich) 
at 10 mU/µL for 1.5 hours at 37°C and stopped by placing 
the samples at −20°C for 15 minutes as previously described.3 
Samples were migrated at 90 V during 1 hour then stained with 
0.5 µg/mL ethidium bromide solution before visualization. 
Captured images were analyzed using Vision-Capt software 
(v 15.06; Vilber Lourmat, Paris, France). Relative amounts 
of dsODN-RecQL1 or dsODN-ApoB (%) were determined 
by comparison of the integrated signal intensity of nuclease-
treated samples versus nontreated samples.
In vitro cell transfection
Cell culture
All cell lines were purchased from American Type Cell 
Culture (Manassas, VA). The HepG2 cell line was cultured in 
minimal essential medium (MEM). The HEK293, Raw294.7, 
and LS174T cell lines were cultured in high-glucose 
Dulbecco’s modified eagle’s media (DMEM-HG). The A549 
and AsPC1 cell lines were cultured in F12-K and Roswell 
Park Memorial Institute medium media, respectively. All 
cell culture media contained 1.85 g/L of sodium bicarbonate 
(NaHCO
3
) and were supplemented with 10% fetal bovine 
serum (Cedarlane Laboratories, Burlington, ON, Canada). 
Table 1 Physicochemical characteristics of bulk chitosans
Chitosan DDA (%)a Mn (kDa)
b Mw (kDa) PDI
c N:P ratiod
92-10 92 10 11.8 1.5 5
80-10 80 10 14.5 1.3 10
80-40 80 40 53.0 1.3 5
80-80 80 80 110.9 1.6 5
Notes: aAs determined by 1H NMr; bas determined by gel permeation 
chromatography (gPC); cMw/Mn; 
dnanopartice N:P ratio follwing complexation with 
either dsODN or sirNA used in this study.
Abbreviations: DDA, degree of deacetylation; Mn, number average molecular 
weight; Mw, specific molecular weight; PDI, polydispersity index; N:P, amine to 
phosphate; dsODN, double-stranded oligodeoxynucleotides.
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All cell lines were cultured at 37°C in a 5% CO
2
 incubator. 
For transfection, cells were plated in 96-well or 24-well 
culture plates (Corning, Lowell, MA) to obtain a ∼50% 
confluence the day of transfection using 100 µL/well or 
500 µL/well, respectively, of complete culture medium.
Cell transfection
For in vitro transfection, DMEM-HG was prepared with 
0.976 g/L of MES and 0.84 g/L of NaHCO
3
 at a pH of 6.5. 
Transfection media containing 10% fetal bovine serum was 
equilibrated overnight at 37°C in a 5% CO
2
 incubator and 
the pH was adjusted to 6.5 using sterile HCl (1N) prior to 
transfection. For siRNA transfection performed in a 96-well 
plate, chitosan/siRNA nanoparticles were prepared as 
described above, 30 minutes before use. A 100 µL siRNA 
solution at a concentration of 0.05 µg/µL was used for siRNA 
complexation with chitosan at a 1:1 ratio (v/v). Following 
complexation, nanoparticles were incubated in a ghost 
plate containing the transfection media (DMEM-HG + fetal 
bovine serum) at a final concentration of 1.35 ng/µL; equivalent 
to 10 pmol per well of siRNA. For dsODN transfection per-
formed in a 24-well plate, nanoparticles were complexed 
as described above and incubated at a final concentration 
of 8.07 ng/µL, equivalent to 60 pmol per well of dsODNs. 
Plates containing nanoparticles were equilibrated for 10 min-
utes at 37°C, 5% CO
2
. Medium over cells was aspirated and 
replenished with either 500 µL (24-well plate) or 100 µL per 
well (96-well plate) of the transfection medium containing 
dsODN- or siRNA-based nanoparticles. Cells were incubated 
with chitosan/siRNA or chitosan/dsODN nanoparticles 
until analysis 24 hours post transfection. The commercially 
available liposome, DharmaFECT™ (Dharmacon RNAi 
 Technologies), was used as a positive control and both 
untreated cells and uncomplexed siRNA/dsODN-treated 
cells were used as negative controls.
Transfection with DharmaFECT
DharmaFECT was used as a positive control for transfec-
tion efficiency in all tested cell lines. DharmaFECT/dsODN 
(flow cytometry and confocal microscopy) or DharmaFECT/
siRNA (qPCR and viability assay) lipoplexes (1:2 [w/v] ratio) 
were prepared following the manufacturer’s protocol.
In vitro cell viability assay
Nanoparticle toxicity was evaluated using the alamarBlue® 
proliferation assay (Invitrogen, Carlsbad, CA). The prin-
ciple of the assay is based on the natural reducing power of 
viable cells to convert resazurin, a blue and nonfluorescent 
 compound, into resofurin; a red and fluorescent molecule. 
Viable cells continuously convert resazurin to resofurin, 
thereby providing a quantitative measure of viability. 
Transfection was performed as described above using 
chitosan-siRNA nanoparticles. Five thousand cells/well 
were seeded 24 hours before transfection. To alleviate the 
experimental bias from the effect of RecQL1 gene silenc-
ing on cell viability, nontargeting siRNA (siRNA mock) 
was used instead. Twenty-four hours post transfection with 
chitosan-based nanoparticles, 20 µL of alamarBlue reagent, 
pre-warmed at 37°C was added to each well and incubated 
for another 4 hours. At the end of the incubation 100 µL of 
media containing reduced alamarBlue dye was transferred 
to a black Corning 96-well plate and read on an infinite 200 
fluorescence plate reader (Tecan Systems, San Jose, CA) 
with excitation 560 nm, emission 590 nm and a cut-off of 
570 nm. Cells without the addition of alamarBlue were used 
as blank and dimethyl sulfoxide was used as a positive con-
trol of toxicity. The viability of nontransfected control cells 
was arbitrarily defined as 100%. The relative cell viability 
was calculated using the following formula: (fluorescence 
intensity
sample
/fluorescence intensity
control
) × 100.
Uptake analysis by flow cytometry  
and confocal microscopy
Fluorescence-activated cell sorting (FACS) analysis
The cellular uptake of dsODNs was determined by transfect-
ing AsPC1, A549, LS174T, HepG2, HEK293, and Raw264.7 
cell lines with nanoparticles formed with (6FAM) 5′labeled 
dsODNs. Twenty-four hours post-transfection, cells were 
chitosanase treated for 60 minutes to eliminate any cell 
surface-associated nanoparticles left from the transfection as 
described previously.3 Afterward, cells were washed twice 
with phosphate-buffered saline, trypsinized, and resuspended 
in phosphate-buffered saline. The analysis of cell uptake was 
made using a BD Canto flow cytometer (Becton Dickinson, 
San Jose, CA). For each sample, 20,000 events were counted 
and to exclude cell debris, dead cells, and aggregated cells, 
a collection gate was established using a dot plot of the 
forward light scatter against the side scatter. Nontransfected 
cells were used as negative controls to discriminate (6FAM) 
positive cells from auto-fluorescence.
Confocal microscopy
For nanoparticle internalization analysis, the LS174T, 
HepG2, HEK293, and Raw264.7 cell lines were seeded on 
35 mm glass-bottom culture dishes (MatTek, A shland, MA) at 
40,000 cells/dish using 500 µL of complete  culture medium. 
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Nanoparticles were formed with fluorescent rhodamine B 
isothiocyanate-labeled chitosan and dsODNs labeled with 
6FAM on their 5′ extremities (Integrated DNA Technologies). 
Prior to imaging, cell membranes were stained with 5 µg/mL 
of Cell Mask™ Deep Red (Invitrogen, Burlington, ON, 
Canada). Images were taken in multitrack mode using a 
Zeiss LSM 510 META confocal Axioplan 200 microscope 
(Carl Zeiss AG, Feldbach, Switzerland). Chitosan and 
dsODNs were visualized as red and green pseudocolors, 
respectively. The spatial overlap of these two colors pro-
duced yellow which permitted a qualitative assessment of 
colocalization.
Quantitative PCr (qPCr) analysis  
of recQL1 and ApoB mrNA knockdown
rNA extraction and assessment methods  
(yield, purity, and integrity)
RNA extraction was performed using the RNA XS® 
 extraction kit from Macherey-Nagel (Biolynx, Montréal, 
QC, Canada) according to the manufacturer’s protocol 
following chitosanase treatment, as described previously.3 
Total RNA was quantified and RNA integrity was measured 
using the Agilent BioAnalyzer 2100 (Agilent Technologies, 
Mississauga, ON, Canada) following the manufacturer’s 
protocol. RNA integrity was evaluated by the ratio of 28S/18S 
ribosomal RNA57 and the RNA integrity number (RIN). The 
Agilent 2100 BioAnalyzer uses automated microfluidics, 
capillary electrophoresis, and fluorescence to evaluate RNA 
integrity. The RIN is a relative measure of RNA quality 
that is based largely on electrophoretic trace analysis. The 
BioAnalyzer 2100 automatically computes RIN, where an 
ideal nondegraded RNA sample has RIN = 10.
reverse transcription
Total RNA was reverse transcribed in a final volume of 
20 µL using the First Strand cDNA Transcriptor Kit (Roche 
Diagnostics, Laval, QC, Canada) with oligodT primers as 
described by the manufacturer’s protocol. Samples were 
stored at −20°C.
gene expression assays
The RecQL1 and ApoB mRNA expression level was deter-
mined using assays designed with the Universal Probe 
Library (UPL) from Roche (Roche Applied Science, Laval, 
QC, Canada). Endogenous control (hypoxanthine guanine 
phosphoribosyl transferase) and glyceraldehyde 3-phos-
phate dehydrogenase expression levels were determined 
using pre-validated TaqMan® Gene Expression Assays 
(Applied Biosystems, Carlsbad, CA). RecQL1 and ApoB 
mRNA (target detection) reactions for 384-well plate formats 
were performed using 1.5 µL of cDNA samples (25–50 ng), 
5 µL of the Fast Universal qPCR MasterMix (Applied Biosys-
tems) 2 µM of each primer, and 1 µM of a Universal Probe 
Library probe (RecQL1 [probe #29]/ApoB [probe #55]) in a 
total volume of 10 µL. For endogenous control assessment, 
reactions were performed using identical volumes of cDNA 
and, Fast Universal qPCR Master Mix, 0.5 µL of the TaqMan 
Gene Expression Assay (20×) and 2.5 µL of water in a total 
volume of 10 µL.
Detection and analysis
The ABI PRISM® 7900HT Sequence Detection System 
(Applied Biosystems) was used to detect the amplifica-
tion level and was programmed with an initial step of 
3 minutes at 95°C, followed by 45 cycles of 5 seconds at 
95°C and 30  seconds at 60°C. All reactions were run in 
triplicate and the average values of Cts (threshold cycle) 
were used for quantification. Glyceraldehyde 3-phosphate 
dehydrogenase and hypoxanthine guanine phosphoribosyl 
transferase were used as endogenous controls. The relative 
quantification of target genes was determined using the 
ρρCT method. Briefly, the Ct values of target genes were 
normalized to an endogenous control gene (endogenous 
control) (∆CT = Ct
target
 – Ct
endoC
) and compared with a 
calibrator: ∆∆CT = ∆Ct
target
 – ∆Ct
calibrator
. Relative expression 
(RQ) was calculated using the Sequence Detection System 
2.2.2  software using the RQ = 2−∆∆CT formula.
Statistical analysis
The statistical analysis was performed using Statistica 
9.0 Software (STATSOFT; Statistica, Tulsa, OK). Data 
are expressed as mean ± standard deviation. Statistical 
significance was determined with one-way analysis of vari-
ance, followed by Tukey’s post hoc test. The results were 
considered significant and highly significant (P , 0.05 and 
P , 0.01, respectively).
Results
Size and ζ-potential of chitosan 
nanoparticles
All formulations of chitosan/dsODN nanoparticles were in 
the range of 41–109 nm as measured by environmental scan-
ning electron microscopy (ESEM) and dynamic light scatter-
ing (Figure 1 and Table 2). Chitosan/dsODN nanoparticles 
showed higher size values with increasing M
n
. No statistically 
significant differences were observed when comparing DDAs 
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for these specific formulations. The excess chitosan in all 
formulations resulted in positively charged nanoparticles as 
shown by ζ-potential measurements (Table 2).
Chitosan/dsODN nanoparticle stability
Chitosan-based nanoparticles were incubated for 0.5, 4, and 
20 hours in two different buffers (pH 6.5 and 8) to assess the 
effect of time and pH on nanoparticle stability (Figure 2). 
Nanoparticles were stable up to 20 hours at an N:P ratio 
above 2 in slightly acidic buffers (pH 6.5). At 4 hours fol-
lowing nanoparticle formation, and under slightly acidic 
 conditions, no detectable dsODNs were observed at N:P 
ratios of 2 or higher (Figure 2A and C). On the contrary, 
dsODN release was observed for the same N:P ratios at a pH 
of 8  (Figure 2B and D). Longer exposure time – 20 hours – at 
a pH of 6.5 resulted in increased dsODN-ApoB release at an 
N:P ratio of 2. This pattern was not observed for the dsODN-
RecQL1 sequence. This may be due to sequence/structural 
differences between the two dsODNs. Furthermore, our 
results at a pH of 8 show a rapid partial-to-complete dsODN 
release after 0.5 hour at an N:P ratio of 2 (Figure 2B and D). 
At N:P ratio 10 and for the same pH of 8, chitosan showed 
a partial release of dsODNs indicating the effect of excess 
chitosan on preserving stability. Overall, our specific chitosan 
formulations assured nanoparticle stability for a minimum 
period of 20 hours at an N:P ratio above 2 in slightly acidic 
near-neutral pH environments.
Nanoparticle protection assay
For effective gene expression and/or inhibition, nucleic acids 
entrapped in the delivery vehicle must be protected from deg-
radation by enzymes such as serum nucleases.58 The ability 
of chitosan-based nanoparticles to protect siRNA mimicking 
dsODN sequences was assessed using a DNAse I protection 
assay against different chitosan formulations complexed 
with dsODN-RecQL1 or dsODN-ApoB. Upon incubatio n 
Figure 1 Environmental scanning electron microscopy images of spherical chitosan/dsODN nanoparticles. (A) 92-10-5 chitosan/dsODN-recQL1 nanoparticles; (B) 80-40-5 
chitosan/dsODN-recQL1 nanoparticles; (C) 80-10-10 chitosan/dsODN-recQL1 nanoparticles; (D) 92-10-5 chitosan/dsODN-ApoB nanoparticles; (E) 80-80-5 chitosan/
dsODN-ApoB nanoparticles, and (F) 80-10-10 chitosan/dsODN-ApoB nanoparticles.
Abbreviations: ApoB, apolipoprotein B; dsODN, double-stranded oligodeoxynucleotide.
Table 2 Size and zeta potential values obtained by dynamic light 
scattering for chitosan/dsODN-recQL1 and chitosan/dsODN-
ApoB nanoparticles
ODN Chitosan Size DLS  
(nm)
Size ESEM  
(nm)
Zeta potential 
(mV)
recQL1 92-10-5  63 ± 8 54 ± 6 23 ± 1
recQL1 80-40-5  86 ± 9 97 ± 12 18 ± 1
recQL1 80-10-10  91 ± 7 73 ± 9 18 ± 2
ApoB 92-10-5  45 ± 4 66 ± 5 21 ± 2
ApoB 80-80-5 100 ± 8 75 ± 13 16 ± 1
ApoB 80-10-10  64 ± 6 67 ± 7 19 ± 2
Notes: Values are mean ± SD; n = 3.
Abbreviations: ApoB, apolipoprotein B; dsODN, double-stranded oligodeoxy-
nucleotides; DLS, dynamic light scattering; ESEM, environmental scanning electron 
microscopy; SD, standard deviation.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1405
Chitosan for polynucleotide delivery
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
69
.7
0.
65
.1
18
 o
n 
21
-A
pr
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2012:7
with DNAse I, naked dsODN-RecQL1 and dsODN-ApoB 
(controls) were completely degraded (Figure 3A–D, lane 3). 
In contrast, DNAse I protection assay showed that all chito-
sans tested protected dsODNs from degradation at DNAse I 
concentrations ,2 units DNAse I per µg dsODN (Figure 3). 
Chitosan formulations demonstrated an average of ∼80% 
protection of dsODNs at DNAse I concentrations of 0.5 U/µg 
(Figure 3). The ability of LMW-CS (92-10, 80-40, 80-80, 
and 80-10) to protect dsODNs from nuclease degradation 
decreased with increased concentrations of DNAse I. Our 
results show that protection decreased from ∼50% at a DNAse 
I concentration of 1 U/µg to less than ∼20% at 2 U/µg (92-10 
and 80-10). Moreover, our results suggest that higher M
n
 chi-
tosan (80-40 and 80-80) offers a slightly  better protection of 
dsODNs as compared to lower M
n
 chitosan (92-10 and 80-10) 
at high DNAse I concentrations (2 U/µg) (Figure 3A–D). The 
enhanced cargo protection observed with higher molecular 
weight chitosans is consistent with previous studies where 
higher binding affinities between high Mw chitosans and 
nucleic acids was demonstrated.59 Altogether, our results 
show that DNAse I protection is considerable when using 
intermediate to low DDA/M
n
 and preserves approximately 
60% of nucleic acid when using 1 unit of DNAse I per µg 
of dsODNs.
In vitro cell uptake analysis by flow 
cytometry and confocal microscopy
Nanoparticle internalization into cells can be another rate-
limiting step for effective drug delivery systems. In general, 
efficient nanoparticle internalization depends on several 
factors, such as the cell type, the physicochemical surface 
properties of the nanoparticles, and the bio–nano  interface.60 
The internalization of RecQL1- and ApoB-bearing nanopar-
ticles was assessed in two different sets of relevant cell lines 
using flow cytometry (FACS). For the assessment of (6FAM) 
dsODN-RecQL uptake, transfection and FACS analysis were 
performed on AsPC1, A549, and LS174T cancer cell lines 
whereas (6FAM) dsODN-ApoB uptake was performed on 
HEK293, HepG2, and Raw269.7 cell lines. Our FACS results 
show that cell uptake using chitosan/(6FAM) dsODN-ApoB 
nanoparticles achieved levels comparable to the commercially 
used lipoplex (DharmaFECT) (Figures 4 and 5), demonstrat-
ing the internalization efficiency of LMW-CS formulations 
in different cell lines. Moreover, our results indicate that 
different chitosan formulations show statistically significant 
differences in their cell uptake efficiency, with LMW-CSs 
92-10-5 and 80-10-10 more easily internalized compared 
to the higher molecular weight 80-80-5 and 80-40-5, in a 
cell-line-dependent manner. Interestingly, the A549 and 
HEK293 cell lines demonstrated no statistical differences 
in uptake efficiency between the different chitosan formula-
tions (Figures 4 and 5A). However, the A549 and HEK293 
cell lines showed statistically significant increases in uptake 
when compared to the LS174T and Raw264.7 cell lines, again 
highlighting some important cell-type dependencies.
In general, LMW-CS (92-10-5 and 80-10-10) showed 
higher uptake efficiency, ranging from approximately 65% to 
95% depending on the transfected cell line (Figures 4 and 5A). 
These results are in accordance with confocal microscopy 
data, where images representative of the whole population 
show that the vast majority of cells for each of the four cell 
types imaged show nanoparticle internalization (Figure 6). 
The lack of colocalization at 24 hours between dsODNs and 
chitosan indicates that complete release of the dsODN cargo 
0N:P
A
B D
C
N:P0.5 2 10 102
4 h20 h 0.5 h 0.5 h20 h 4 h
0 0.5 1020 0.5 1020 0.5 1020 0.5 1020 0.5
Figure 2 Chitosan nanoparticle temporal stability. Stability was assessed at 0.5, 4, and 24 hours after complex formation using polyacrylamide gel electrophoresis at a pH 
of 6.5 (MES 1X) and pH8 (TAE 1X). Chitosan 92-10 at different N:P ratios (0.5, 2, and 10) was complexed with: (A) dsODN-recQL1 at a pH of 6.5; (B) dsODN-recQL1 
at a pH of 8; (C) dsODN-ApoB at a pH of 6.5, and (D) dsODN-ApoB at a pH of 8. Unstable nanoparticles release dsODNs which become visible following EtBr staining on 
polyacrylamide gel following ethidium bromide staining of the polyacrylamide gel.
Abbreviations: ApoB, apolipoprotein B; dsODN, double-stranded oligodeoxynucleotide; N:P, amine to phosphate.
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Figure 3 Nuclease protection assays of chitosan/dsODN nanocomplexes. (A) Chitosan (92-10-5, 80-40-5 or 80-10-10) complexed with dsODN-recQL1. (B) dsODN-recQL1 
remaining after the DNAse I digestion was assessed using the signal intensity of the treated samples with the control (ie, 0 U DNAse I = 100% intensity). This comparison was 
made between the samples of the same chitosan formulation. (C) Chitosans (92-10-5, 80-80-5 or 80-10-10) complexed with dsODN-ApoB. (D) dsODN-ApoB remaining 
after the DNAse I digestion was similarly assessed as in (B).
Abbreviations: ApoB, apolipoprotein B; dsODN, double-stranded oligodeoxynucleotide.
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Figure 4 Cellular uptake of dsODN-recQL1 nanoparticles 24 hours post transfection in AspC1, A549, and LS174T cancer cell lines. Chitosan formulations 92-10-5, 
80-40-5, and 80-10-10 were complexed to (6FAM) 5′ labeled dsODN-RecQL1 and transfected at 60 pmol/well 24 hours prior to fluorescence-activated cell sorting analysis. 
DharmaFECT™ was used as the positive uptake control.
Notes: Values are mean ± SD; n = 3; **P . 0.01.
Abbreviations: dsODN, double-stranded oligodeoxynucleotide; SD, standard deviation.
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Figure 5 Cellular uptake of dsODN-ApoB nanoparticles 24 hours post transfection in HEK293, raw269.7, and Hepg2 cell lines. Chitosan formulations 92-10-5, 80-80-5, 
and 80-10-10 were complexed to (6FAM) 5′ labeled dsODN-ApoB and transfected at 60 pmol/well 24 hours prior to fluorescence-activated cell sorting analysis. (A) Uptake 
efficiency of dsODN-ApoB in percentage (%). (B) Uptake efficiency of dsODN-ApoB in HepG2 cells at different passage numbers. DharmaFECT™ was used as the positive 
uptake control.
Notes: Values are mean ± SD; n = 3; *P . 0.05; **P . 0.01.
Abbreviations: ApoB, apolipoprotein B; dsODN, double-stranded oligodeoxynucleotide; SD, standard deviation.
Figure 6 Confocal imaging of chitosan/dsODN nanocomplex uptake 24 hours post transfection. Chitosan 92-10 (DDA, Mn) was labeled with rhodamine (red) and dsODNs 
were 5′ labeled with (6FAM) (green). Chitosan 92-10 was complexed to dsODNs at an N:P ratio of 5. Cell membranes were stained prior to imaging with CellMask™ (blue) 
to differentiate between internalized and membrane-bound nanoparticles. Images shown represent each separate channel, with dsODNs in green, chitosan in red, membrane 
in blue, differential interference contrast image in grey, and the merged images shown on the bottom left quadrant. (A) LS174T cells transfected with chitosan/dsODN-
recQL1 nanoparticles. (B) Hepg2 cells transfected with chitosan/dsODN-ApoB nanoparticles. (C) HEK293 cells transfected with chitosan/dsODN-ApoB nanoparticles. 
(D) raw 294.7 cells transfected with chitosan/dsODN-ApoB nanoparticles.
Abbreviations: ApoB, apolipoprotein B; dsODN, double-stranded oligodeoxynucleotide; N:P, amine to phosphate.
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was achieved 24 hours post transfection. Furthermore, the 
diffuse staining pattern of dsODNs seen in most transfected 
cells suggests that complexes have escaped endocytic vesicles 
(Figure 6), consistent with previous live cell imaging work 
using chitosan–plasmid DNA nanoparticles.40
Specific gene silencing and cell 
cytotoxicity evaluation of chitosan 
nanoparticles in different cell lines
Gene silencing occurs when complementarity is achieved 
between the siRNA seed region and target mRNA.1 
 Chitosan-specif ic formulations (92-10-5, 80-40-5, 
80-10-10, and 80-80-5) were assessed for mRNA knock-
down in two different cell lines relevant to cancer and 
atherosclerosis, targeted by RecQL1 and ApoB siRNA, 
respectively. qPCR analysis revealed inhibition of RecQL1 
and ApoB since their coding mRNAs were downregulated 
more than twofold (Figure 7). More specifically, in LS174T 
cells, chitosan 92-10-5 showed a high level of silencing 
(∼80%) of RecQL1, similar to the current commercial gold 
standard liposomal formulation (∼80%), used here as a 
p ositive control.  Formulations 80-40-5 and 80-10-10 also 
induced significant silencing but to a lower degree than 
92-10-5 and also with an increase of nonspecific mock 
silencing, especially for formulation 80-10-10, for reasons 
that remain to be elucidated. For the HepG2 cell line, only the 
best performing 92-10-5 was tested and induced significant 
silencing (∼55% versus ∼80% for positive control) of ApoB 
but slightly lower than RecQL1 for LS174T. Importantly, our 
results showed that silencing efficiency with chitosan reached 
similar levels to the positive control, with a markedly reduced 
cytotoxicity from the delivery system as assessed using the 
alamarBlue assay (Figure 8).
Discussion
In this study, we evaluated the efficiency of specific low 
molecular weight chitosan (LMW-CS) formulations at 
low N:P ratios for the in vitro delivery of siRNA targeting 
either RecQL1 or ApoB genes. RecQL1 is a DNA helicase 
playing a major role in homologous recombination, main-
tenance of genomic stability, and DNA repair at damaged 
replication forks.52,61 Overexpression of RecQL1 has been 
implicated in cancer by preventing cell apoptosis.6,7,62 As 
for ApoB, it is a major gene involved in atherosclerosis 
through its essential role in the formation of very low den-
sity lipoprotein which will therefore generate low density 
lipoproteins following triacylglycerol hydrolyzation in the 
circulation.51,63,64
DharmaFECT™DharmaFECT™
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Figure 7 real-time polymerase chain reaction analysis of the inhibition of recQL1 and ApoB gene expression in specific cell lines. LS174T cells were transfected with chitosan 
(92-10-5, 80-40-5, and 80-10-10)/sirNA-recQL1 nanoparticles, whereas Hepg2 cells were transfected with chitosan (92-10-5)/sirNA-ApoB nanoparticles. The inhibition 
percentage was obtained by comparing the transfected and nontransfected cells, using the ∆∆CT method.
Notes: Values are mean ± SD; n = 3; **P . 0.01.
Abbreviations: ApoB, apolipoprotein B; sirNA, small interfering rNA; SD, standard deviation.
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Nanoparticle size is one parameter affecting uptake and 
intracellular trafficking, both considered as potential rate-
limiting steps for effective gene therapy.41,42 For instance, 
nano-sized particles have been shown to be internalized more 
efficiently than micro-sized particles.65–67 In this study, LMW-
CS-based nanoparticles ranged in size from 41–110 nm, 
a size range promoting uptake, prolonged blood circulation, 
higher tissue penetration, and a relatively free passage from 
the mononuclear phagocyte system.48,68–70 Therefore, our 
results show that these specific LMW-CS nanoparticles at 
low N:P ratios meet performance criteria (Table 3) and are 
potentially relevant for in vivo administration. The differ-
ent chitosan parameters – DDA, M
n
, and N:P ratios – used 
in this study did not significantly affect nanoparticle size, 
with higher molecular weight chitosan promoting a slightly 
increased size (Table 1). Our results are in contrast to previ-
ously published reports where the authors found increased 
nanoparticle size for lower molecular weight chitosan.43 
This discrepancy may be due to differences in experimental 
conditions and to the high N:P ratio used in Liu et al and 
Howard et al reports8,43 versus low N:P ratios reported in our 
study. ESEM analysis revealed that these small nanoparticles 
were of spherical shape consistent with previous findings for 
pDNA,37 siRNA,8 and dsODNs.71 The effect of nanoparticle 
shape on internalization efficiency showed spherical particles 
of similar size being internalized 500% more efficiently 
than rod-shaped particles.72–74 This is mainly explained by 
increased membrane-wrapping time required for elongated 
particles and greater thermodynamic forces required for 
their engulfment.60,74 It was previously demonstrated that 
the morphology of chitosan-pDNA nanoparticles is strongly 
dependent upon their charge ratios, and the variation of the 
latter resulted in nanoparticles with different topological con-
formations including spherical,75 toroidal,76,77 and globular 
morphologies.76,78 Chitosan-based nanoparticle shape may 
also seem to be affected by the type of nucleic acid – pDNA 
or siRNA/dsODN – used for complexation and the process 
of nanoparticle formation; ie, ionic gelation. The fact that 
these LMW-CS nanoparticles demonstrated a reproducible 
pattern of spherical particles at low N:P ratios may be indica-
tive of higher internalization efficiency than nanoparticles of 
different topological conformations.
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Figure 8 Cell viability assessment using the alamarBlue® assay 24 hours post transfection with different chitosan/sirNA formulations. To alleviate the apoptotic effect of 
recQL1 gene silencing for a proper assessment of chitosan-sirNA toxicity, mock sirNA was used for transfection in the LS174T cell line. The Hepg2 cell line was transfected 
with ApoB sirNA. DharmaFECT™ was used for comparison purposes whereas dimethyl sulfoxide was used as a positive control of toxicity.
Notes: Values are presented as mean ± SD; n = 3.
Abbreviations: ApoB, apolipoprotein B; sirNA, small interfering rNA.
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Nanoparticle stability and nucleic acid protection are 
important parameters for efficient nucleic acid delivery. Our 
results of nuclease protection indicate that all LMW-CS for-
mulations tested were able to protect dsODNs at supraphysi-
ological concentrations of nucleases. Nuclease protection 
is of great importance for nucleic acid delivery systems 
through maintenance of cargo bioavailability and improved 
pharmacokinetic profile, thereby increasing the therapeutic 
potential of these nanoparticles. Increasing chitosan  molecular 
weight resulted in an enhanced cargo protection (Figure 3) 
in agreement with previous findings.17,38,42,43,46 Nevertheless, 
enhancing the ability of nanoparticles to protect their siRNA 
from degradation may render their intracellular disassembly 
more difficult, as demonstrated with high molecular weight 
chitosan-pDNA nanoparticles.40 Further characterization of 
nanoparticle stability by gel retardation assays show that 
LMW-CS used at low N:P ratios can effectively complex and 
compact dsODNs into stable particles. We found LMW-CS 
nanoparticles at N:P ratios above 2 to be stable in slightly 
acidic buffers for at least 20 hours. These interesting findings 
are in contrast with most previous studies using chitosan-
siRNA nanoparticles, where high M
n
 and high N:P ratios are 
usually required to achieve particle stability.8,17,42,43,79 This 
discrepancy can be explained by the lower pH (pH 6.5) of the 
electrophoresis buffer in our study compared to the commonly 
used TAE buffer at a pH of 8 for chitosan-based nanopar-
ticle characterization,8,17,42,43,80 a difference that was clearly 
highlighted by our gel retardation assay performed at both 
pHs (Figure 2). The use of a lower pH in the electrophoresis 
buffer results in higher degrees of chitosan ionization which 
translates to stronger electrostatic attraction to the polyanionic 
nucleic acid and hence more stable nanoparticles. This simple 
modification of the pH permits lower N:P ratios than those 
observed previously8,17,42,43,80 to achieve nanoparticle stabil-
ity. A direct consequence of this modification translates into 
reduced dosing, aggregation, and other undesirable nonspe-
cific effects of large quantities of soluble chitosan for in vivo 
delivery where nanoparticles are to be injected at physiologi-
cal pH values close to the chitosan pK
a
 of 6.5.
In general, efficient nanoparticle internalization depends 
on factors such as cell type, physicochemical surface proper-
ties of the nanoparticles, and the bio–nano interface.60 In this 
report, we demonstrated that LMW-CS nanoparticles were 
efficiently internalized in multiple cell lines. The uptake 
efficiency as measured by flow cytometry ranged from 50% 
(Raw269.7) to 95% (A549 and HEK293), depending on the 
cell line. Statistical analysis of uptake efficiency intercell lines 
showed meaningful differences when comparing the A549 
and HEK293 (high uptake) to the LS174T and Raw269.7 
(medium uptake), indicating a cell-line dependency of 
chitosan uptake. The cell-line dependency of chitosan nano-
particles uptake was previously suggested to be associated 
with different endocytic pathways.81,82 Flow cytometry data 
Table 3 Safety and performance criteria for the development of 
effective nonviral gene delivery systems
Categories Performance criteria**
Physical and  
chemical properties
•  Nanoparticle formation/assembly at a nucleic 
acid scale of 10 mg, from the perspective of 
size, shape, aggregation, and charge, as well as 
from an efficacy standpoint (such as toxicity 
and transfection efficacy), should be  
similar/reproducible each time  
nanoparticles are formed at this and lower 
concentrations
•  Assemblies less than 300 nm, PDI (,0.3) and 
no less than 80% incorporation efficiency
• No aggregation in 50% mouse/human serum
• Chemical stability of the assembly for .30 days
•  Preferably amenable to freeze-drying 
without any loss of its performance criteria
Activity in cell  
based assays*
•  .50% reducation in target mrNA by target 
specific siRNA at concentrations ,100 nm 
in 10% serum containing media
•  ,10% reduction in target mrNA by control 
sirNA at concentrations ,100 nm in 10% 
serum containing media
•  .5-fold window between target gene silencing 
IC50 and IC50 for reduction in viability
•  Activity in at least relevant 3 cell lines to the 
delivery system under evaluation
Performance and  
safety in animal  
models
•  .50% reduction in target mrNA levels by 
target sirNA and ,10% reduction in target 
mrNA levels in target tissue at 1 mg/kg dose 
by control sirNA by 24–48 hr
•  Demonstration of rNAi-mediated target 
mrNA cleavage by 5’-rACE
•  ,10-fold cytokine induction (TNFα, IFNβ, 
IL6) and ,10-fold increase in ALT and AST 
at 3 mg/kg sirNA dose
•  No effect on body weight and normal blood 
clinical chemistry and hematology data
• Lack of immunogenicity
•  Lack of auto-antibodies and anti-DNA 
antibodies
• Lack of systemic toxicity
•  No effect on body weight and normal blood 
clinical chemistry and hematology data
Notes: *If the delivery platform incorporates a targeting moiety evidence should be 
provided for targeting by (a) using cell lines with differential expression of targeted 
receptor and (b) using assemblies with “active” and “inactive or mutant” targeting 
moieties; **performance criteria described here are for both sirNA and plasmid DNA 
delivery systems. The criteria in this table has been adapted from information in US 
FDA84,85 and US Pharmacopeia.86
Abbreviations: PDI, polydispersity index; mrNA, messenger rNA; sirNA, small 
interfering RNA; IC50, half maximal inhibitory concentration; RACE, rapid amplification 
of cDNA ends; ALT, alanine transaminase; AST, aspartate transaminase.
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showed LMW-CS nanoparticles to be efficiently internal-
ized to levels similar or higher than commercially available 
liposomal systems such as DharmaFECT.
Finally, the transfection efficiency of LMW-CS nanopar-
ticles as measured by gene-silencing efficacy was evaluated in 
two different cell lines: RecQL1 in LS174T cells and ApoB in 
HepG2 cells. The ability of these chitosan formulations to effi-
ciently silence gene expression reached more than a twofold 
specific mRNA knockdown; with chitosan 92-10-5 being the 
most efficient and specific in the LS174T cell line. Other low 
molecular weight formulations also achieved good levels of 
gene silencing in the LS174T cell line. Interestingly, chitosan 
80-10-10 achieved a high level of silencing with a concomi-
tant increase in silencing when delivering mock siRNA. This 
intriguing observation is currently under investigation in our 
laboratory. The chitosan formulation 92-10-5 complexed to 
ApoB siRNA showed lower target mRNA knockdown in 
HepG2 when compared to the LS174T cell lines targeted 
with the RecQL1 siRNA. The silencing efficiency correlated 
well with uptake efficiency as observed by flow cytometry 
where chitosan 92-10-5 showed both high uptake and high 
silencing efficiencies. Despite structural differences between 
pDNA and siRNA,46 the chitosan formulation 92-10-5 has 
shown the highest transfection efficiencies for both siRNA 
and pDNA to date.37–41 Taken together, our results show that 
LWM-CS nanoparticles at low N:P ratios can achieve effi-
cient uptake and gene silencing in vitro, serving as a proof 
of concept for their use as efficient siRNA delivery vectors in 
cancer and atherosclerotic animal models. Although in vitro 
and in vivo performance criteria differ, no consensus on such 
performances has been established. For in vivo performance, 
safety remains the major issue, with guidance available from 
the US Food and Drug Administration for the development of 
gene and cell therapy products.83 Therefore, the development 
of nonviral drug delivery systems for in vivo use should take 
into account physicochemical criteria, cell-based criteria, 
and, most importantly, in vivo performance and safety cri-
teria (Table 3). The low molecular weight, low N:P system 
presented here meets many of these criteria and has already 
been demonstrated as efficient in vivo for plasmid DNA 
delivery.37,41 Thus a complete characterization of the safety 
and in vivo performance of our LMW-CS system delivering 
RecQL1 and ApoB targeting siRNA is currently under inves-
tigation in animal models of cancer and atherosclerosis.
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